Browse result page of B3Pdb

The total number entries retrieved from this search are 507, scroll left/right for detailed information.
B3pdbIDPEPTIDE NAMEPEPTIDE SEQUENCE (1-letter)PEPTIDE SEQUENCE (3-letter)N-TERMINAL MODIFICATIONC-TERMINAL MODIFICATION CHEMICAL MODIFICATIONPEPTIDE LENGTHPEPTIDE CONFORMATIONPEPTIDE NATURESOURCE/ORIGIN OF PEPTIDESMILESCELL LINEIn vitro CONCENTRATIONIn vitro METHODIn vitro RESULTANIMAL MODELIn vivo CONCENTRATIONIn vivo MODE OF DELIVERYIn vivo METHODIn vivo RESULTACTIONTRANSPORT TYPESUBCELLULAR LOCALISATIONCOMBINATIONPHYSICAL CONDITIONRESPONSERESULTLABELPMID
b3pdb_1150BeauvericinNANANANANA6LinearNAChemically synthesizedNANANAEfflux study ICUNANANANANANA NA Permeability NA NA NA Brain elemination rate constant -0.1205 min-1 Direct iodination 27349679
b3pdb_1151BeauvericinNANANANANA6LinearNAChemically synthesizedNANANACapillary depletionNANANANANANA NA NA NA NA NA % parenchyma 91.92% Direct iodination 27349679
b3pdb_1152BeauvericinNANANANANA6LinearNAChemically synthesizedNANANACapillary depletionNANANANANANA NA NA NA NA NA % parenchyma 8.08% Direct iodination 27349679
b3pdb_1153BeauvericinNANANANANA6LinearNAChemically synthesizedNANANANANANANAIntravenous NANA NA Permeability NA NA NA Unidirectional influx rate constant 0.01115 mL/(g x min) Direct iodination 27349679
b3pdb_1154BeauvericinNANANANANA6LinearNAChemically synthesizedNANANANANANANAIntravenous NANA NA Permeability NA NA NA Initial disrobution volume 0.02191 ml/g Direct iodination 27349679
b3pdb_1155PepH1VQQLTKRFSLValGlnGlnLeuThrLysArgPheSerLeuNANANA10LinearNAChemically synthesizedN[C@@]([H])(C(C)C)C(=O)N[C@@]([H])(CCC(=O)N)C(=O)N[C@@]([H])(CCC(=O)N)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])([C@]([H])(O)C)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])(CCCNC(=N)N)C(=O)N[C@@]([H])(Cc1ccccc1)C(=O)N[C@@]([H])(CO)C(=O)N[C@@]([H])(CC(C)C)C(=O)ONANAInitial concentration in donor chamber-CultureNANANANANANA NA Permeability NA NA NA Translocated 73.83% 99mTc(CO)3+ 28263555
b3pdb_1156PepH1VQQLTKRFSLValGlnGlnLeuThrLysArgPheSerLeuNANANA10LinearNAChemically synthesizedNANANANANANANAIntravenous NANA NA Permeability NA NA NA % injected dose 0.02 %/g 99mTc(CO)3+ 28263555
b3pdb_1164MEL1201H-YPW-(Ph)Map-NH2H-Tyr-Pro-Trp-(Ph)Map-NH2NANANA3LinearNAChemically synthesizedNANANAanti-nociceptionNANANANANANA NA Permeability NA NA NA ED50 5.32 mg/kg NA 26116761
b3pdb_1165MEL1209H-YPW-(3-ClPh)Map-NH2H-Tyr-Pro-Trp-(3-ClPh)Map-NH2NANANA3LinearNAChemically synthesizedNANANAanti-nociceptionNANANANANANA NA Permeability NA NA NA ED50 28.58 mg/kg NA 26116761
b3pdb_1166MEL1214H-YPW-(2-furyl)Map-NH2H-Tyr-Pro-Trp-(2-furyl)Map-NH2NANANA3LinearNAChemically synthesizedNANANAanti-nociceptionNANANANANANA NA Permeability NA NA NA ED50 3.14 mg/kg NA 26116761
b3pdb_1167MEL1224H-YPW-(2-furyl)Map-NH2H-Tyr-Pro-Trp-(3-furyl)Map-NH2NANANA3LinearNAChemically synthesizedNANANAanti-nociceptionNANANANANANA NA Permeability NA NA NA ED50 4.02 mg/kg NA 26116761
b3pdb_1168PepNegSGTQEEYSer-Gly-Thr-Gln-Glu-Glu-TyrNANANA7LinearNAChemically synthesizedNANANAInitial concentration in donor chamber-CultureNANANANANANA NA Permeability NA NA NA Translocated 42.50% NA 29057814
b3pdb_1169C-36cKFFDDmt-c[D-Lys-Phe-Phe-Asp]NH2NANANA4LinearNAChemically synthesizedNANANANANANANANANANA NA NA NA NA NA NA NA NA NA
b3pdb_1170F-81NADmt-c[D-Lys-Phe-p-CF3-Phe-Asp]NH2NANANA4LinearNAChemically synthesizedNANANANANANANANANANA NA NA NA NA NA NA NA NA NA
b3pdb_1171LLVV-H4LLVVYPWTLeu-Leu-Val-Val-Tyr-Pro-Trp-ThrNANANA8LinearNAChemically synthesizedNANANANANANANANANANA NA NA NA NA NA NA NA NA NA
b3pdb_1172LVV-H4LVVYPWTLeu-Val-Val-Tyr-Pro-Trp-ThrNANANA7LinearNAChemically synthesizedNANANAInitial concentration in donor chamber-CultureNANANANANANA NA Permeability NA NA NA Area 3.2 Counts NA 29692758
b3pdb_1179RD2D3PTLHTHNRRRRRRPRTRLHTHRNRPro-Thr-Leu-His-Thr-His-Asn-Arg-Arg-Arg-Arg-Arg-Arg-Pro-Arg-Thr-Arg-Leu-His-Thr-His-Arg-Asn-ArgNANANA24LinearNAChemically synthesizedNANANANANANANAIntravenous NANA NA Permeability NA NA NA Brain to plasma ratio 0.6 H3/C14 27086111
b3pdb_1180RD2D3PTLHTHNRRRRRRPRTRLHTHRNRPro-Thr-Leu-His-Thr-His-Asn-Arg-Arg-Arg-Arg-Arg-Arg-Pro-Arg-Thr-Arg-Leu-His-Thr-His-Arg-Asn-ArgNANANA24LinearNAChemically synthesizedNANANANANANANAIntravenous NANA NA Permeability NA NA NA Peak response 0.3 µL/(g x min) H3/C14 27086111
b3pdb_1181RD2D3PTLHTHNRRRRRRPRTRLHTHRNRPro-Thr-Leu-His-Thr-His-Asn-Arg-Arg-Arg-Arg-Arg-Arg-Pro-Arg-Thr-Arg-Leu-His-Thr-His-Arg-Asn-ArgNANANA24LinearNAChemically synthesizedNANANANANANANAIntravenous NANA NA Permeability NA NA NA Unidirectional influx rate constant 0.0003 ml/(g x min) H3/C14 27086111
b3pdb_1182RD2D3PTLHTHNRRRRRRPRTRLHTHRNRPro-Thr-Leu-His-Thr-His-Asn-Arg-Arg-Arg-Arg-Arg-Arg-Pro-Arg-Thr-Arg-Leu-His-Thr-His-Arg-Asn-ArgNANANA24LinearNAChemically synthesizedNANANANANANANAIntravenous NANA NA Permeability NA NA NA Initial disrobution volume 0.0512 ml/g H3/C14 27086111
b3pdb_1183cRD2D3PTLHTHNRRRRRRPRTRLHTHRNRPro-Thr-Leu-His-Thr-His-Asn-Arg-Arg-Arg-Arg-Arg-Arg-Pro-Arg-Thr-Arg-Leu-His-Thr-His-Arg-Asn-ArgNANANA24LinearNAChemically synthesizedNANANANANANANAIntravenous NANA NA Permeability NA NA NA Peak response 2 µL/(g x min) H3/C14 29225107
b3pdb_1184cRD2D3PTLHTHNRRRRRRPRTRLHTHRNRPro-Thr-Leu-His-Thr-His-Asn-Arg-Arg-Arg-Arg-Arg-Arg-Pro-Arg-Thr-Arg-Leu-His-Thr-His-Arg-Asn-ArgNANANA24LinearNAChemically synthesizedNANANANANANANAIntravenous NANA NA Permeability NA NA NA Unidirectional influx rate constant 0.002 ml/(g x min) H3/C14 29225107
b3pdb_1185cRD2D3PTLHTHNRRRRRRPRTRLHTHRNRPro-Thr-Leu-His-Thr-His-Asn-Arg-Arg-Arg-Arg-Arg-Arg-Pro-Arg-Thr-Arg-Leu-His-Thr-His-Arg-Asn-ArgNANANA24LinearNAChemically synthesizedNANANANANANANAIntravenous NANA NA Permeability NA NA NA Initial disrobution volume 0.1955 ml/g H3/C14 29225107
b3pdb_1186AH-DSGSWLRDVWDWICTVLTDFKTWLQSKLSer-Gly-Ser-Trp-Leu-Arg-Asp-Val-Trp-Asp-Trp-Ile-Cys-Thr-Val-Leu-Thr-Asp-Phe-Lys-Thr-Trp-Leu-Gln-Ser-Lys-LeuNANANA27LinearNAChemically synthesizedNANANANANANANAIntravenous NANA NA Permeability NA NA NA Unidirectional influx rate constant 0.0003853 mL/(g x min) NA 30349030
b3pdb_1187AH-DSGSWLRDVWDWICTVLTDFKTWLQSKLSer-Gly-Ser-Trp-Leu-Arg-Asp-Val-Trp-Asp-Trp-Ile-Cys-Thr-Val-Leu-Thr-Asp-Phe-Lys-Thr-Trp-Leu-Gln-Ser-Lys-LeuNANANA27LinearNAChemically synthesizedNANANANANANANAIntravenous NANA NA Permeability NA NA NA Initial disrobution volume 0.0060268 ml/g NA 30349030
b3pdb_1188NT2Cav-RPYILCav-Arg-Pro-Tyr-Ile-LeuNANANA6LinearNAChemically synthesizedNANANANANANANAPAMPANANA NA Permeability NA NA NA Translocated 85% NA 30374780
b3pdb_1189NT4R-Cav-PYILArg-Cav-Pro-Tyr-Ile-LeuNANANA6LinearNAChemically synthesizedNANANANANANANAPAMPANANA NA Permeability NA NA NA Translocated 90% NA 30374780
b3pdb_1190Macrocyclic inhibitocGflGGrrrGfGGIGGcCys-Gly-Phe-Leu-Gly-Gly-Arg-Arg-Arg-Gly-Phe-Gly-Gly-Ile-Gly-Gly-CysNANANA17LinearNAChemically synthesizedNANANAInitial concentration in donor chamber-CultureNANANANANANA NA Permeability NA NA NA Parallel artificial membrane permeation assay apparent permiability cofficient 14.6 cm/s Fluorescent label 29908130
b3pdb_1191Gly-ProGPGly-ProNANANA2LinearNAChemically synthesizedNANANANANANANAin situ brain perfusionNANA NA Permeability NA NA NA Unidirectional flux rate constant 0.00349 mL/(g x min) NA 30962462
b3pdb_1192Gly-ProGPGly-ProNANANA2LinearNAChemically synthesizedNANANANANANANAin situ brain perfusionNANA NA Permeability NA NA NA Brain/perfusate ratio 10.9 NA 30962462
b3pdb_1193Tyr-ProTPTyr-ProNANANA2LinearNAChemically synthesizedNANANANANANANAin situ brain perfusionNANA NA Permeability NA NA NA Unidirectional flux rate constant 0.00353 mL/(g x min) NA 30962462
b3pdb_1194Tyr-ProTPTyr-ProNANANA2LinearNAChemically synthesizedNANANANANANANAin situ brain perfusionNANA NA Permeability NA NA NA Brain/perfusate ratio 10.5 NA 30962462
b3pdb_1195mouse Des-octanoyl GGSSFLSPEHQKAQQRKESKKPPAKLQPRGly-Ser-Ser-Phe-Leu-Ser-Pro-Glu-His-Gln-Lys-Ala-Gln-Gln-Arg-Lys-Glu-Ser-Lys-Lys-Pro-Pro-Ala-Lys-Leu-Gln-Pro-ArgNANANA28LinearNAChemically synthesizedNANANANANANANAIntravenous NANA NA Permeability NA NA NA Unidirectional influx rate constant 0.0002606 mL/(g x min) Direct iodination 30293893
b3pdb_1196mouse Des-octanoyl GGSSFLSPEHQKAQQRKESKKPPAKLQPRGly-Ser-Ser-Phe-Leu-Ser-Pro-Glu-His-Gln-Lys-Ala-Gln-Gln-Arg-Lys-Glu-Ser-Lys-Lys-Pro-Pro-Ala-Lys-Leu-Gln-Pro-ArgNANANA28LinearNAChemically synthesizedNANANANANANANAIntravenous NANA NA Permeability NA NA NA Initial disrobution volume 0.002265 ml/g Direct iodination 30293893
b3pdb_1197ANK6RKRIRLVTKKKRArg-Lys-Arg-Ile-Arg-Leu-Val-Thr-Lys-Lys-Lys-ArgNANANA12LinearNAChemically synthesizedNANANANANANANAIntravenous NANA NA Permeability NA NA NA Peak response 0.3 µL/(g x min) H3/C14 29966196
b3pdb_1198ANK6RKRIRLVTKKKRArg-Lys-Arg-Ile-Arg-Leu-Val-Thr-Lys-Lys-Lys-ArgNANANA12LinearNAChemically synthesizedNANANANANANANAIntravenous NANA NA Permeability NA NA NA Unidirectional influx rate constant 0.0003 mL/(g x min) H3/C14 29966196
b3pdb_1199ANK6RKRIRLVTKKKRArg-Lys-Arg-Ile-Arg-Leu-Val-Thr-Lys-Lys-Lys-ArgNANANA12LinearNAChemically synthesizedNANANANANANANAIntravenous NANA NA Permeability NA NA NA Initial disrobution volume 0.0575 ml/g H3/C14 29966196
b3pdb_1203cANK6rRKRIRLVTKKKRRArg-Lys-Arg-Ile-Arg-Leu-Val-Thr-Lys-Lys-Lys-Arg-ArgNANANA13LinearNAChemically synthesizedNANANANANANANAIntravenous NANA NA Permeability NA NA NA Peak response 0.3 µL/(g x min) H3/C14 29966196
b3pdb_1204PEP inhibitory peptiPPLPro-Pro-LeuNANANA3LinearNAChemically synthesizedNANANANANANANAIntravenous NANA NA Permeability NA NA NA Unidirectional influx rate constant 0.0003 mL/(g x min) H3/C14 29966196
b3pdb_1205OP5NFDVLTEQAsn - Phe - Asp - Val - Leu - Thr - Glu - GlnNANANA8LinearNAChemically synthesizedNANANANANANANAIntravenous NANA NA Permeability NA NA NA Unidirectional influx rate constant 0.0396 ml/g H3/C14 29966196
b3pdb_1206SLSHSPQSLSHSPQSer - Leu - Ser - His - Ser - Pro - GlnNANANA7LinearNAChemically synthesizedNANANANANANANANANANA NA NA NA NA NA NA NA NA NA
b3pdb_1207NTGSPYENTGSPYEAsn - Thr - Gly - Ser - Pro - Tyr - GluNANANA7LinearNAChemically synthesizedNANANANANANANANANANA NA NA NA NA NA NA NA NA NA
b3pdb_1209PenetratinRQIKIWFQNRRMKWKKNANANANA16LinearNAChemically synthesizedNANANANANAMale Sprague-Dawley rats2.0 mMIntranasalELISAL-penetratin increased the systemic absorption of leptin after intranasal administration. The intranasal coadministration with L-penetratin could deliver leptin to the brain and in particula Permeability Hypothalamus Combined with leptin Obesity NA The intranasal coadministration with L-penetratin has a potential to deliver leptin into the therape NA 31926192
b3pdb_1210PHT-TGN-HBcTGNYKALHPHNGNANANANA12LinearNAChemically synthesizedNAHuman astrocytes HA18000.2 mg PHT/kgConfocal MicroscopyNAMice0.2 mg PHT/kgIntravenous VIS Lumina II Spectrum Imaging SystemIt demonstrated high penetration ability PHT-TGN-HBc NCs showed high antiepileptic effects in epilepsy mouse model with no side effects Permeability Cerebral vasculature Comined with phenytoin and hepatitis B core Refractory Epilepsy It prolongs the circulation time of the drug and efficiently load large amount of drugs, and showed It efficiently target the brain tissue by 2.4 fold and increase the antiepileptic efficiency of phen NA 32087458
b3pdb_1211P15VQITYKNAN-terminal acetylationC-terminal amidationNA6LinearNAChemically synthesizedNAHuman brain endothelial cells (EA.hy926)NAField-emission transmission electron microscopeA3 peptide treated with this peptide, showed higher folds of decrease in fluorescence intensities aNANANANANA Trojan peptides are capable of translo- cating the BBB, without affecting its interity. Translocation NA Comined with A3 pepide Tauopathies These peptides were capable of reducing the tau elicit toxicity by accelerating or impeding the self These peptide-based modulators (Trojans) were non-amyloidogenic, stable in serum and showed minimal NA 32114026
b3pdb_1212P16VQILYKNAN-terminal acetylationC-terminal amidationNA6LinearNAChemically synthesizedNAHuman brain endothelial cells (EA.hy926)NAField-emission transmission electron microscopeA3 peptide treated with this peptide, showed higher folds of decrease in fluorescence intensities aNANANANANA Trojan peptides are capable of translo- cating the BBB, without affecting its interity. Translocation NA Comined with A3 pepide Tauopathies These peptides were capable of reducing the tau elicit toxicity by accelerating or impeding the self These peptide-based modulators (Trojans) were non-amyloidogenic, stable in serum and showed minimal NA 32114026
b3pdb_1213P17VQIIYKNAN-terminal acetylationC-terminal amidationNA6LinearNAChemically synthesizedNAHuman brain endothelial cells (EA.hy926)NAField-emission transmission electron microscopeA3 peptide treated with this peptide, showed higher folds of decrease in fluorescence intensities aNANANANANA Trojan peptides are capable of translo- cating the BBB, without affecting its interity. Translocation NA Comined with A3 pepide Tauopathies These peptides were capable of reducing the tau elicit toxicity by accelerating or impeding the self These peptide-based modulators (Trojans) were non-amyloidogenic, stable in serum and showed minimal NA 32114026
b3pdb_1214P18VQIVYKNANAC-terminal amidationNA6LinearNAChemically synthesizedNAHuman brain endothelial cells (EA.hy926)NAField-emission transmission electron microscopeA3 peptide treated with this peptide, showed higher folds of decrease in fluorescence intensities aNANANANANA Trojan peptides are capable of translo- cating the BBB, without affecting its interity. Translocation NA Comined with A3 pepide Tauopathies These peptides were capable of reducing the tau elicit toxicity by accelerating or impeding the self These peptide-based modulators (Trojans) were non-amyloidogenic, stable in serum and showed minimal NA 32114026
b3pdb_1215P19VQILYKNANAC-terminal amidationNA6LinearNAChemically synthesizedNAHuman brain endothelial cells (EA.hy926)NAField-emission transmission electron microscopeA3 peptide treated with this peptide, showed higher folds of decrease in fluorescence intensities aNANANANANA Trojan peptides are capable of translo- cating the BBB, without affecting its interity. Translocation NA Comined with A3 pepide Tauopathies These peptides were capable of reducing the tau elicit toxicity by accelerating or impeding the self These peptide-based modulators (Trojans) were non-amyloidogenic, stable in serum and showed minimal NA 32114026
b3pdb_1216P20VQIYKNANAC-terminal amidationNA6LinearNAChemically synthesizedNAHuman brain endothelial cells (EA.hy926)NAField-emission transmission electron microscopeA3 peptide treated with this peptide, showed higher folds of decrease in fluorescence intensities aNANANANANA Trojan peptides are capable of translo- cating the BBB, without affecting its interity. Translocation NA Comined with A3 pepide Tauopathies These peptides were capable of reducing the tau elicit toxicity by accelerating or impeding the self These peptide-based modulators (Trojans) were non-amyloidogenic, stable in serum and showed minimal NA 32114026